PhRMA, navigating turbulence, taps Gilead CEO to helm board of directors

Wednesday, the Pharmaceutical Research and Manufacturers of America (PhRMA) revealed that Gilead Sciences CEO Daniel O’Day has donned the mantle as chair of the board, replacing Novartis chief Vas Narasimhan, who held the position for much of 2023.